弥漫性胶质瘤是成人最常见的脑肿瘤之一，与不良预后相关，尤其是胶质母细胞瘤患者。迄今为止，肿瘤组织采集对于最终诊断和治疗决策是必需的。在这项研究中，我们的目的是确定脑脊液（CSF）和血液中可能的诊断和预后生物标志物。在我们机构的神经胶质瘤手术期间，从患者身上采集了脑脊液和血液样本。随后，使用靶向代谢组学分析来检测和量化循环代谢物。将神经胶质瘤患者的代谢组谱与因其他实体（例如非神经胶质瘤或脑积水）接受神经外科手术的对照组患者的代谢组谱进行比较，并与已建立的神经胶质瘤诊断分子标志物相关。 在这项研究中，总共有 30 个神经胶质瘤包括 21 名无神经胶质瘤患者的对照组。血清代谢组学分析未检测到各组之间存在任何显着差异，而脑脊液代谢组学分析显示胶质瘤患者中六种代谢物的水平增加。其中，生物胺腐胺存在最显着的差异（p = 0.00005）。对甲酚硫酸盐被确定为确定神经胶质瘤患者异柠檬酸脱氢酶 (IDH) 状态的潜在 CSF 标记物 (p = 0.0037)。与血液分析不同，CSF 代谢组分析显示出作为神经胶质瘤患者诊断工具的前景，有潜力分配分子亚型。下一步将涉及更大规模的多中心研究来验证这些发现，最终目标是将脑脊液代谢组学分析纳入临床实践。© 2024。作者。

Diffuse gliomas are among the most common brain tumors in adults and are associated with a dismal prognosis, especially in patients with glioblastoma. To date, tumor tissue acquisition is mandatory for conclusive diagnosis and therapeutic decision-making. In this study, we aimed to identify possible diagnostic and prognostic biomarkers in cerebrospinal fluid (CSF) and blood.During glioma surgery at our institution, CSF and blood samples were collected from patients. Subsequently, targeted metabolomics analysis was used to detect and quantify circulating metabolites. The metabolome profiles of glioma patients were compared with those of patients in a control group who had undergone neurosurgery for other entities, such as nonglial tumors or hydrocephalus, and were correlated with established glioma diagnostic molecular markers.In this study, a total of 30 glioma patients were included, along with a control group of 21 patients without glioma. Serum metabolomic analysis did not detect any significant differences between the groups, whereas CSF-metabolome analysis revealed increased levels of six metabolites in glioma patients. Among these, the most pronounced differences were found for the biogenic amine putrescine (p = 0.00005). p-Cresol sulfate was identified as a potential CSF marker for determining isocitrate dehydrogenase (IDH) status in glioma patients (p = 0.0037).CSF-metabolome profiling, unlike blood profiling, shows promise as a diagnostic tool for glioma patients with the potential to assign molecular subtypes. The next step will involve a larger multicenter study to validate these findings, with the ultimate objective of integrating CSF metabolomics analysis into clinical practice.© 2024. The Author(s).